Morgan Stanley Aligos Therapeutics, Inc. Transaction History

Morgan Stanley

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Aug 16, 2024	BUY	$0.64 - $1.13 $832 - $1,468	1,300 Added 65.0%	3,300 $3,000
Q1 2024 May 15, 2024	BUY	$0.64 - $1.13 $832 - $1,468	1,300 Added 65.0%	3,300 $3,000
Q4 2023 Aug 16, 2024	SELL	$0.56 - $0.8 $728 - $1,040	-1,300 Reduced 39.39%	2,000 $1,000
Q3 2023 Nov 15, 2023	SELL	$0.71 - $1.06 $710 - $1,060	-1,000 Reduced 33.33%	2,000 $1,000
Q2 2023 Aug 14, 2023	SELL	$0.89 - $1.36 $115,454 - $176,424	-129,724 Reduced 97.74%	3,000 $2,000
Q1 2023 May 15, 2023	BUY	$0.87 - $2.11 $113,422 - $275,082	130,371 Added 5540.63%	132,724 $115,000
Q4 2022 Feb 14, 2023	SELL	$0.89 - $28.0 $7,056 - $222,012	-7,929 Reduced 77.12%	2,353 $2,000
Q3 2022 Nov 14, 2022	SELL	$1.06 - $27.5 $44,870 - $1.16 Million	-42,331 Reduced 80.46%	10,282 $11,000
Q2 2022 Oct 27, 2022	SELL	$1.04 - $2.14 $28,596 - $58,843	-27,497 Reduced 34.32%	52,613 $64,000
Q2 2022 Aug 15, 2022	SELL	$1.04 - $2.14 $28,596 - $58,843	-27,497 Reduced 34.32%	52,613 $64,000
Q1 2022 Oct 27, 2022	BUY	$2.08 - $12.2 $57,193 - $335,463	27,497 Added 52.26%	80,110 $171,000
Q1 2022 May 13, 2022	BUY	$2.08 - $12.2 $59,155 - $346,968	28,440 Added 55.04%	80,110 $171,000
Q4 2021 Feb 14, 2022	SELL	$11.48 - $17.69 $4.8 Million - $7.39 Million	-417,734 Reduced 88.99%	51,670 $613,000
Q3 2021 Nov 15, 2021	BUY	$14.57 - $17.72 $6.84 Million - $8.32 Million	469,404 New	469,404 $7.28 Million

227K

Ticker ALGS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,717,000
Market Cap $1.66B
Description
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.